While Pacific Biosciences' earnings were beat, shrinking sales, high debt, and poor macro environment do not inspire ...

Genomics company Pacific Biosciences of California (NASDAQ:PACB) reported Q1 CY2025 results , but sales fell by 4.3% year on ...

Rapidly mutating DNA regions were mapped using a multi-generational family and advanced sequencing tools. Understanding how ...

Genomics company Pacific Biosciences of California (NASDAQ:PACB) will be reporting results tomorrow after market close.

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, delivered an adjusted loss per share of 15 cents in first-quarter 2025, narrower than the year-ago adjusted loss of 26 ...

GAAP net loss for the first quarter of 2025 was $426.1 million, compared to $78.2 million for the first quarter of 2024.

PacBio has announced the conclusion of its Special Committee's independent investigation into allegations related to employment practices and cybersecurity raised by an attorney for a former ...

MENLO PARK, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced it plans to improve on its ...

Collaboration leverages HiFi's unique ability to reveal hidden variants, bringing a new level of precision to early life genetic screening ...

Genomics company Pacific Biosciences of California (NASDAQ:PACB) reported Q1 CY2025 results beating Wall Street’s revenue expectations , but sales fell by 4.3% year on year to $37.15 million.

Despite strong Service and other revenues, PACB reports soft first-quarter 2025 results partly due to lower Revio system ...